Method for detecting and treating cancer with adenosine pathway activation

摘要

The present disclosure provides a method of detecting the expression level of one or more genes in a subject having or suspected of having cancer, and optionally an adenosine pathway antagonist in combination with a PD-1 inhibitor and/or a PD-L1 inhibitor, e.g. , A method of treating cancer by treating the subject with an adenosine A2A receptor (ADORA2A) antagonist. The genes include, but are not limited to, CD68, CD163, EBP, CCL2, CCL3, CCL7, CCL24, CCNE1, CD14, CD300E, CD86, CD93, CLEC5A, CSF3, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL8, DFNA5, ECEL1 , EPB41L3, EHF, FUT7, GALM, GBP6, GPR157, HAS1, IL1A, IE-1β, IL23, IL24, IL5, IL6, IL8, INHBA, LAP3, LAYN, LOC100505585, MRPL11, NID1, OST4, PADI2, PID1, PLAUR , PPBP, PTGS2, RHCG, SERPINB2, SLC11A1, SLC7A7, SPON1, ST6GALNAC2, TBX21, THBS1, C1R, C1S, C4BPA, CCL11, CCL20, CXCL16, CXCL2, HAMP, HSD11B1, SAFR5, TSF14 , TREM2, APP, ATG10, BCL2, CCL15, CD24, CD46, CD59, CREB5, CX3CL1, CXCL14, CYFIP2, DEFB1, DPP4, ECSIT, EPCAM, IFIT1, IGF1R, ITGA6, ITGB3, MAP2K4, MAPK1, MASP , SPA17, STAT5B, TOLLIP, AKT3, BMI1, CD164, CD34, CDH5, CREB1, DOCK9, ENG, HMGB1, ITGA1, JAM3, MAF, MAPK3, MAPK8, MCAM, MFGE8, NOTCH1, NRP1, PRKCE, SMAD2, TALHY1 , TNFSF12, TRAF6, TXNIP, VEGFA, S100A8, and/or WDR83OS.